Pnc Financial Services Group, Inc. C4 Therapeutics, Inc. Transaction History
Pnc Financial Services Group, Inc.
- $148 Billion
- Q4 2024
A detailed history of Pnc Financial Services Group, Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 15,768 shares of CCCC stock, worth $34,374. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,768
Previous 15,842
0.47%
Holding current value
$34,374
Previous $90,000
37.78%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
125Shares Held
62.7MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$15.2 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$14.9 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$13.2 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$10.6 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$9.92 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $107M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...